United Therapeutics Corporation (UTHR)

United Therapeutics Corp has consistently displayed strong liquidity ratios over the past five years, indicating its ability to meet short-term obligations without relying heavily on external financing.

The current ratio, which measures the company's ability to cover its short-term liabilities with its current assets, has shown a generally increasing trend, reaching 4.41 in 2023 from 4.03 in 2019. This implies that the company's current assets are more than sufficient to cover its current liabilities, providing a comfortable buffer for operational needs.

Similarly, the quick ratio, which is a more stringent measure of liquidity as it excludes inventory from current assets, has also exhibited an upward trajectory, standing at 4.28 in 2023 compared to 3.83 in 2019. This suggests that United Therapeutics Corp has a strong ability to meet its short-term obligations with its most liquid assets, such as cash and marketable securities.

Furthermore, the cash ratio, which represents the company's ability to cover its current liabilities with cash and cash equivalents alone, has shown a consistent improvement over the years, reaching 3.93 in 2023 from 3.50 in 2019. This indicates that United Therapeutics Corp holds a sufficient level of cash reserves to meet its short-term financial commitments without the need to liquidate other current assets.

In conclusion, United Therapeutics Corp's liquidity ratios demonstrate a sound financial position, with ample liquidity to manage its short-term obligations effectively.

---

Additional liquidity measure

The cash conversion cycle of United Therapeutics Corp has shown a declining trend over the past five years, indicating improvements in the efficiency of its working capital management. In 2023, the company's cash conversion cycle decreased to 194.27 days from 277.26 days in 2022. This suggests that United Therapeutics is converting its investments in inventory and accounts receivable into cash more quickly, which is a positive sign for the company's liquidity and operational efficiency.

Comparing to 2021 and 2020, where the cash conversion cycle was 311.19 days and 316.96 days respectively, United Therapeutics has made significant progress in streamlining its cash conversion process. The decreasing trend in the cash conversion cycle reflects the company's ability to optimize its cash flows and effectively manage its working capital requirements.

Even though there was a slight increase in the cash conversion cycle in 2019 (297.31 days), the overall trend demonstrates a positive development in United Therapeutics' financial management. By continuing to focus on efficiently converting its assets into cash, the company can enhance its financial performance and strengthen its position in the market.